Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors

This study is testing a new medication called gotistobart to see if it works better than standard chemotherapy for patients with advanced lung cancer. It is for people whose cancer continued to grow after receiving common immunotherapy treatments.

The study is for adults over 18 who have advanced non-small cell lung cancer that has grown despite previous treatment with chemotherapy and immunotherapy. Participants must be in good enough health to handle the treatments and meet specific requirements regarding their previous medical history.

Participants will be randomly assigned to receive either gotistobart or a standard chemotherapy drug called docetaxel. Both treatments are given through an IV infusion every 21 days for up to one year.

This study is currently active but is no longer recruiting new participants. It is taking place at various medical sites across the United States, including locations in Alabama, Arkansas, and California.